References
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 https://doi.org/10.1093/jnci/92.3.205
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
- Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404-410
- Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759 https://doi.org/10.1200/JCO.2006.07.3049
- Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, et al. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-456 https://doi.org/10.1148/radiol.2512081403
- Lee HY, Han J, Lee KS, Koo JH, Jeong SY, Kim BT, et al. Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 2009;66:379-385 https://doi.org/10.1016/j.lungcan.2009.02.011
- Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006;6:S126-S130 https://doi.org/10.1102/1470-7330.2006.9039
- Gwyther SJ. Current standards for response evaluation by imaging techniques. Eur J Nucl Med Mol Imaging 2006;33:11- 15 https://doi.org/10.1007/s00259-006-0130-6
- Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-4445 https://doi.org/10.1200/JCO.2004.07.960
- Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008;191:133-139 https://doi.org/10.2214/AJR.07.2848
- Kan Z, Phongkitkarun S, Kobayashi S, Tang Y, Ellis LM, Lee TY, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 2005;237:151- 158 https://doi.org/10.1148/radiol.2363041293
Cited by
- Imaging assessment of tumor response: past, present and future vol.7, pp.5, 2010, https://doi.org/10.2217/fon.11.38
- Tumor Size Evaluation according to the T Component of the Seventh Edition of the International Association for the Study of Lung Cancer's TNM Classification: Interobserver Agreement between Radiologis vol.65, pp.4, 2010, https://doi.org/10.3348/jksr.2011.65.4.381
- Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts vol.13, pp.4, 2010, https://doi.org/10.3348/kjr.2012.13.4.371
- Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response? vol.13, pp.6, 2012, https://doi.org/10.3348/kjr.2012.13.6.702
- Comparison of the Diagnostic Performance of Response Evaluation Criteria in Solid Tumor 1.0 with Response Evaluation Criteria in Solid Tumor 1.1 on MRI in Advanced Breast Cancer Response Evaluation to vol.14, pp.1, 2010, https://doi.org/10.3348/kjr.2013.14.1.13
- Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy? vol.9, pp.2, 2010, https://doi.org/10.1371/journal.pone.0088598
- Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab vol.8, pp.None, 2015, https://doi.org/10.2147/ott.s87101
- Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer vol.21, pp.11, 2010, https://doi.org/10.1007/s12094-019-02072-4
- Imaging of Novel Oncologic Treatments in Lung Cancer Part 1 : Systemic Therapies vol.35, pp.1, 2020, https://doi.org/10.1097/rti.0000000000000451
- Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib vol.146, pp.2, 2010, https://doi.org/10.1007/s00432-019-03064-1
- Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer vol.42, pp.6, 2010, https://doi.org/10.1053/j.sult.2021.04.015